Skip to content
Research Article Open access CC BY 3.0

Listeria Meningitis After Infliximab in Ulcerative Colitis: Does the Risk of Treatment Outweigh the Benefit

Iyad A Issa, Ali Eid

Journal of Advances in Medicine and Medical Research · pp. 2008–2016 · Published 28 Jun 2013

10.9734/BJMMR/2013/4691

Abstract

Biologic agents have become important treatment options for the management of inflammatory bowel disease (IBD). With more than 10 years of experience behind us these agents have changed the natural history of the disease and have established themselves as a valid choice in the repertoire used in treating not only advanced patients but also newly diagnosed ones. We report two cases of ulcerative colitis who developed listeria meningitis after a single dose of infliximab therapy. We also examined the significance of the infection and the known details and morbidity about it. We assessed the close link between the use of biologics and the risk of serious infections in patients with IBD, as well as the published cases in the literature so far. Therefore, despite the excitement and hype surrounding their use we should not forget that these are agents that carry a substantial toll of side effects and this should be kept in mind when the choice of therapy is made.

Listeria monocytogenes meningitis ulcerative colitis infliximab biologic agents

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

4

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.